InspireMD (NSPR) Scheduled to Post Quarterly Earnings on Tuesday

InspireMD (NASDAQ:NSPR) will announce its earnings results before the market opens on Tuesday, May 14th. Analysts expect the company to announce earnings of ($2.50) per share for the quarter.

InspireMD (NASDAQ:NSPR) last announced its quarterly earnings results on Tuesday, February 19th. The company reported ($0.05) earnings per share for the quarter. The business had revenue of $0.82 million during the quarter.

NASDAQ:NSPR opened at $4.45 on Friday. InspireMD has a 52 week low of $4.01 and a 52 week high of $82.00.

Separately, HC Wainwright restated a “buy” rating on shares of InspireMD in a research report on Wednesday, March 13th.

TRADEMARK VIOLATION NOTICE: “InspireMD (NSPR) Scheduled to Post Quarterly Earnings on Tuesday” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2019/05/12/inspiremd-nspr-scheduled-to-post-quarterly-earnings-on-tuesday.html.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions.

Featured Article: Support Level

Earnings History for InspireMD (NASDAQ:NSPR)

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply